Initial Management of MRONJ Stages I and II, a Clinical Trial With Detection of Salivary Biomarkers

Osteonecrosis of the Jaw, Bisphosphonate Induced Clinical Trial

Official title:

Conservative Versus Surgical Treatment for Medication Related Osteonecrosis of the Jaws (MRONJ) Stages I and II, a Quasi-experimental Clinical Trial With Discovery of Salivary Biomarkers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04584840
• Other study ID #: CI-202-17
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2020
• Est. completion date: January 15, 2024

Study information

• Verified date: February 2021
• Source: Fundació d'investigació Sanitària de les Illes Balears
• Contact: JUAN M ZÁRATE GONZÁLEZ, MD
• Phone: +34636794627
• Email: JUANLAK[@]HOTMAIL.COM
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication in patients receiving antiresorptive therapies, such as Bisphosphonates and Denosumab. It is defined by the presence of exposed bone or a fistula that probes bone in the jaws for a period greater than 8 weeks in patient with a history of current or past antiresorptive or antiangiogenic treatment, and in the absence of prior radiotherapy or maxillary bone metastases. Depending on the severity of the disease 4 stages are described.

On the other hand, although the presence of alterations in the levels of certain biomarkers in saliva has been documented in patients with MRONJ compared to healthy patients, its applicability in clinical practice is still unknown.

Until recently, the status quo favored the adoption of a conservative strategy (non-surgical) for the initial management of patients with stage I and II. However, in recent years, this paradigm has been challenged by multiple authors who report better and more predictable outcomes with surgical treatment.

Based on the hypothesis that patients with MRONJ stage I and II subjected to initial surgical treatment have better results than those undergoing conservative (non-surgical) treatment, te research group has designed a unicentric, quasi-experimental clinical trial where the clinical and radiological outcome at the third month of 2 groups of patients with stages I and II MRONJ undergoing non-surgical treatment (Group 1 / control) versus initial surgical treatment (Group 2 / intervention) will be compared.

Also, the investigators hypothesize that the patients with complete resolution of the disease will also normalize salivary biomarkers levels unlike those with stable or progressive disease, meaning there is a correlation between clinical and biochemical response. Accordingly, the levels of specific salivary biomarkers at baseline and at the third month will be determined and compared with the clinical outcome.

After enrollment patients will be instructed and offered both treatment strategies, and assigned to the corresponding group according to their choice. Patients in group 1 (non-surgical) will receive traditional conservative treatment while patients undergoing surgical treatment will receive the same guidelines of conservative treatment plus surgery according to a specific surgical protocol.

Description:

1. Type of study: unicentric quasi-experimental clinical trial

2. Hypothesis:

2.1. Patients with MRONJ stage I and II subjected to initial surgical treatment have better results than those undergoing conservative (non-surgical) treatment.

2.2. There is a correlation between clinical and biochemical outcome and the detection in saliva of certain biomarkers such as Amino Terminal Crosslinked Telopeptides of Type 1 Collagen (NTX), Matrix metallopeptidase 9 (MMP-9), Interleukin 1a (IL-1a), Interleukin 1b (IL-1b), Interleukin 6 (IL-6), Interleukin 17 (IL-17) and Interleukin 36α (IL-36α) may be useful to monitor treatment response.

3. Main Objectives:

3.1. To compare the clinical and radiological outcome after 3 months of conservative treatment versus initial surgical treatment in patients with MRONJ stage I and II.

3.2. To determine the levels of salivary biomarkers at the beginning and after 3 months of treatment while correlating them with the clinical outcome.

4. Secondary Aims

• To determine if there is a relationship between the initial surface of exposed bone and the outcome.

• To determine if clinical and radiological concordance in the outcome at the third month for each group.

• To determine the rate of postoperative complications in the surgical group.

• To determine if there is a relationship between the number of surgical interventions and the outcome.

• To determine the percentage of patients undergoing conservative treatment which eventually end up requiring surgical treatment due to disease progression.

• To determine the elapsed time until complete healing for both groups.

• To determine the variables associated with a higher cure rate.

• To determine the variables associated with increased risk of disease progression or recurrence.

5. MATERIAL AND METHODS 5.1. Sample Size Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a bilateral contrast, 21 patients per group are required to detect a cure rate of 30% and 70% in the conservative and surgical treatment group, respectively. Adding 10% to cover possible experimental losses, the sample increases to 23 per group.

5.2. Main Variables

• MRONJ Stage (1. Stage 1; 2. Stage 2).

• Type of treatment (GROUP 1/Control: Conservative Treatment, GROUP 2: Surgical Treatment).

• Clinical outcome at the third month

• Radiological outcome at the third month

• Levels of biomarkers in saliva at baseline and at the third month (NTX, MMP-9, IL-1a, IL-1b, IL-6, IL-17 and IL-36α). In the case scientific evidence of other relevant markers appears during the course of the study they may be included in the study.

5.3. Secondary Variables 5.3.1. Both groups

• Age (years)

• Sex (1.Man; 2.Mother)

• Diabetes (1. Yes; 2. No)

• Medication associated with the disease (1. Oral bisphosphonates, 2. Intravenous Bisphosphonates, 3. Denosumab, 4: Antiangiogenic).

• Underlying disease for antiresorptive therapy (1. Osteoporosis, 2. Cancer)

• Duration of treatment with medication associated with the disease.

• Factor that triggers the disease (1. Tooth Extraction; 2. Use of removable prosthesis;

3. Unclear cause)

• Suspension of medication associated with the development of MRONJ (1. Yes, 2. No)

• Concomitant treatment with corticosteroids (1. Yes, 2. No)

• Concomitant treatment with antiangiogenic drugs (1. Yes, 2. No)

• Visual Analogue Scale (VAS) pain in the inclusion visit, and in all follow-up visits.

• Exposed bone surface (1. mild: <0,5cm2; 2. Moderate: 0,5-2cm2; Severe:> 2cm2) or number of intraoral fistulas otherwise.

• Dimension of greater diameter of radiolucent area or sequestrum in the CT or Cone Beam-CT scan (cm)

• Time elapsed until complete healing.

• Recurrence.

5.3.2. Group 1 (Conservative medical treatment)

• Need for surgical treatment due to disease progression

• Time elapsed until surgical rescue treatment due to disease progression.

5.3.3. Group 2 (Surgical treatment)

• Postoperative complications.

• Number of interventions.

5.4. Inclusion Visit

• Patients will be informed about the different aspects of the study and will be given the information sheet to read carefully. Informed consent document will be given to read and sign.

• A thorough medical history will be collected including data about their socio-family environment, psychiatric illnesses and addictions.

• Complete and careful physical examination of the head and neck area will be carried out, including the measurement of the area of exposed bone in cm2 or, otherwise, the number of fistulas. Based on the clinical findings, stage 1 or 2 will be assigned according to the AAOMS guidelines.

• Once verified that the patient meets the inclusion criteria, patients will be assigned to the corresponding group according to their chosen treatment strategy.

• Radiological assessment will be carried out with Orthopantomography and CT-scan/Cone Beam-CT in all patients.

• Both groups will receive the same standard conservative treatment according to our protocol, meaning group 1 (non-surgical) will serve as control group.

• For patients enrolled in the surgical group, routine preoperative exams will be requested and surgical intervention will be scheduled within a maximum period of 3 weeks from the inclusion visit following a rigorous and standardized surgical protocol.

5.4.1 STANDARD PROTOCOL FOR CONSERVATIVE TREATMENT (applicable to both groups)

• Soft diet.

• Suspension of the use of prostheses or intraoral devices.

• Oral hygiene guidelines.

• Topical antiseptics: in the form of mouthrinses with 0.12% chlorhexidine after every meal and clorhexidine gel over the exposed bone or fistula.

• Systemic antibiotics: for patients in stage 2 in which active acute infection is detected with Amoxicillin/Clavulanic Acid 875/125 mg every 8 hours for 2 weeks. Those allergic to penicillin will receive clindamycin 300 mg every 8 hours for 2 weeks or Levofloxacin 500 mg / day for 2 weeks. Systemic antibiotics treatment can be prolonged indefinitely until infection and symptoms are controlled.

5.4.2. SPECIFIC PROTOCOL FOR SURGICAL TREATMENT

• Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.

• Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.

• Secure a two layered waterproof closure without tension (simple or with local flaps).

• Samples will be sent for Pathological and microbiological analysis.

• Stitches removal after two weeks

• Postoperative systemic antibiotic following the mentioned protocol until stitches removal.

5.4.3. SALIVA COLLECTION PROTOCOL

• Patients must avoid rinsing and ingestion of solids or liquids for at least 1 hour prior to collection.

• The collection will take place between 8 and 10 am.

• Five minutes after an oral rinse with distilled water, 5 ml of unstimulated full saliva from the lower lip will be collected.

• The samples will be processed within the first hour of collection of the sample by centrifuging at 2,600 x g for 15 minutes at 4 ° C. The supernatant will be collected and stored at -80 ° C until the biomarkers are analyzed.

5.4.4. SUCCESSIVE VISITS

• Controls will be carried out 2 weeks after the inclusion visit and then monthly until the third month when the outcomes will be determined and the second sample of saliva will be collected. Long term follow-up will continue every three to six months depending on patient characteristics and desires.

• At each visit, the following information will be recorded: symptoms with VAS for pain; physical examination of head and neck; presence of exposed bone and surface in cm2 or number of fistulas otherwise. If complete mucosal healing is found, the time elapsed since the start of treatment will be recorded.

• Patients in GROUP 1, may develop disease progression refractory to conservative management. In that case, the second saliva sample will be collected before the third month and previous to surgical treatment.

• Patients of GROUP 2 with persistent disease, recurrence or significant worsening will undergo revision surgery if accepted.

• Radiological follow-up will be carried out with orthopantomography and CT scan/Cone Beam-CT at the third month.

5.4.5. STATISTICAL ANALYSIS Normality tests and graphs will be used to determine if the variables follow a normal distribution. Variables with normal distribution are expressed as mean ± standard deviation and those without normal distribution are expressed as median and interquartile range. To evaluate the differences between groups, the student's t test or the Mann-Whitney U test will be used for quantitative variables; and the chi-square test or Fisher's exact test for qualitative variables.

The correlations will be examined by the Spearman or Pearson rank correlation. Paired or related sample tests will be used to assess intragroup differences. A value of p <0.05 will be considered an indicator of a significant difference.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: January 15, 2024
• Est. primary completion date: October 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of stage I or stage II medication related osteonecrosis of the jaws (MRONJ) according to the 2014 AAOMS position paper.

Exclusion Criteria:

• Coexistence of any medical or social condition that prevents proper adherence to treatment or follow-ups (dependent patients without adequate socio-familiar support, drug addiction, severe psychiatric illness, terminal disease with life expectancy less than 3 months).

• Coexistence of Brown's Tumor, Paget's Disease or other bone diseases with the exception of Osteoporosis or bone metastases.

Related Conditions & MeSH terms

• Bisphosphonate-Associated Osteonecrosis of the Jaw
• Osteonecrosis
• Osteonecrosis of the Jaw, Bisphosphonate Induced
• Osteonecrosis of the Jaw, Bisphosphonate Related

Intervention

Procedure:
• Surgical treatment
Same guidelines as group 1 (non-surgical) plus surgical treatment according to the following protocol: Specific protocol for surgical treatment Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm. Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules. Secure a two layered waterproof closure without tension (simple or with local flaps). Samples will be sent for Pathological and microbiological analysis. Stitches removal after two weeks Postoperative systemic antibiotic following the mentioned protocol until stitches removal.

Locations

Country	Name	City	State
Spain	Hospital Universitario Son Espases	Palma de Mallorca	Baleares

Sponsors (1)

Lead Sponsor	Collaborator
Fundació d'investigació Sanitària de les Illes Balears

Country where clinical trial is conducted

Spain, 

References & Publications (23)

Bagan J, Sáez GT, Tormos MC, Hens E, Terol MJ, Bagan L, Diaz-Fernández JM, Lluch A, Camps C. Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws. Oral Dis. 2014 Jul;20(5):446-52. doi: 10.1111/odi.12150. Epub 2013 Jul 10. — View Citation

Bagan J, Sheth CC, Soria JM, Margaix M, Bagan L. Bisphosphonates-related osteonecrosis of the jaws: a preliminary study of salivary interleukins. J Oral Pathol Med. 2013 May;42(5):405-8. doi: 10.1111/jop.12021. Epub 2012 Nov 15. — View Citation

Bedogni A, Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, Bettini G, Di Fede O, Oteri G, Fusco V, Gabriele M, Ottolenghi L, Valsecchi S, Porter S, Petruzzi M, Arduino P, D'Amato S, Ungari C, Fung Polly PL, Saia G, Campisi G. Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. Br J Oral Maxillofac Surg. 2014 Sep;52(7):603-8. doi: 10.1016/j.bjoms.2014.04.009. Epub 2014 May 22. — View Citation

Bedogni A, Fusco V, Agrillo A, Campisi G. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis. 2012 Sep;18(6):621-3. doi: 10.1111/j.1601-0825.2012.01903.x. Epub 2012 Feb 22. — View Citation

Carlson ER. Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. J Oral Maxillofac Surg. 2014 Apr;72(4):655-7. doi: 10.1016/j.joms.2013.12.007. Epub 2013 Dec 15. Review. — View Citation

El-Rabbany M, Sgro A, Lam DK, Shah PS, Azarpazhooh A. Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J Am Dent Assoc. 2017 Aug;148(8):584-594.e2. doi: 10.1016/j.adaj.2017.04.002. Epub 2017 May 18. Review. — View Citation

Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, Miyamoto H, Shibuya Y, Ueda N, Kirita T, Nakahara H, Shinohara M, Umeda M. Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis. J Bone Miner Res. 2017 Oct;32(10):2022-2029. doi: 10.1002/jbmr.3191. Epub 2017 Jul 11. — View Citation

Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017 Jan;35(1):6-19. doi: 10.1007/s00774-016-0810-7. Epub 2016 Dec 29. Review. Erratum in: J Bone Miner Metab. 2017 Jan;35(1):20. — View Citation

Kim S, Williams DW, Lee C, Kim T, Arai A, Shi S, Li X, Shin KH, Kang MK, Park NH, Kim RH. IL-36 Induces Bisphosphonate-Related Osteonecrosis of the Jaw-Like Lesions in Mice by Inhibiting TGF-ß-Mediated Collagen Expression. J Bone Miner Res. 2017 Feb;32(2):309-318. doi: 10.1002/jbmr.2985. Epub 2016 Oct 12. — View Citation

Kolokythas A, Karras M, Collins E, Flick W, Miloro M, Adami G. Salivary Biomarkers Associated With Bone Deterioration in Patients With Medication-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg. 2015 Sep;73(9):1741-7. doi: 10.1016/j.joms.2015.03.034. Epub 2015 Mar 19. — View Citation

Lerman MA, Xie W, Treister NS, Richardson PG, Weller EA, Woo SB. Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. Oral Oncol. 2013 Sep;49(9):977-983. doi: 10.1016/j.oraloncology.2013.05.012. Epub 2013 Jul 3. — View Citation

Lesclous P, Grabar S, Abi Najm S, Carrel JP, Lombardi T, Saffar JL, Samson J. Relevance of surgical management of patients affected by bisphosphonate-associated osteonecrosis of the jaws. A prospective clinical and radiological study. Clin Oral Investig. 2014;18(2):391-9. doi: 10.1007/s00784-013-0979-2. Epub 2013 Apr 19. — View Citation

Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7. — View Citation

Mücke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell DA, Wolff KD, Hölzle F. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol. 2011 May;137(5):907-13. doi: 10.1007/s00432-010-0953-1. Epub 2010 Oct 7. — View Citation

Nørholt SE, Hartlev J. Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients. Int J Oral Maxillofac Surg. 2016 Oct;45(10):1256-60. doi: 10.1016/j.ijom.2016.04.010. Epub 2016 May 11. — View Citation

Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C. Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg. 2015 Mar;43(2):290-3. doi: 10.1016/j.jcms.2014.11.014. Epub 2014 Nov 22. Review. — View Citation

Ristow O, Rückschloß T, Müller M, Berger M, Kargus S, Pautke C, Engel M, Hoffmann J, Freudlsperger C. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Craniomaxillofac Surg. 2019 Mar;47(3):491-499. doi: 10.1016/j.jcms.2018.12.014. Epub 2018 Dec 29. — View Citation

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. doi: 10.1016/j.joms.2014.04.031. Epub 2014 May 5. Erratum in: J Oral Maxillofac Surg. 2015 Jul;73(7):1440. J Oral Maxillofac Surg. 2015 Sep;73(9):1879. — View Citation

Ruggiero SL, Kohn N. Disease Stage and Mode of Therapy Are Important Determinants of Treatment Outcomes for Medication-Related Osteonecrosis of the Jaw. J Oral Maxillofac Surg. 2015 Dec;73(12 Suppl):S94-S100. doi: 10.1016/j.joms.2015.09.024. — View Citation

Schiodt M, Reibel J, Oturai P, Kofod T. Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Feb;117(2):204-13. doi: 10.1016/j.oooo.2013.10.010. Epub 2013 Nov 15. — View Citation

Thumbigere-Math V, Michalowicz BS, de Jong EP, Griffin TJ, Basi DL, Hughes PJ, Tsai ML, Swenson KK, Rockwell L, Gopalakrishnan R. Salivary proteomics in bisphosphonate-related osteonecrosis of the jaw. Oral Dis. 2015 Jan;21(1):46-56. doi: 10.1111/odi.12204. Epub 2013 Nov 29. — View Citation

Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 2009 Feb;20(2):331-6. doi: 10.1093/annonc/mdn630. Epub 2008 Oct 26. — View Citation

Zhang Q, Atsuta I, Liu S, Chen C, Shi S, Shi S, Le AD. IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin Cancer Res. 2013 Jun 15;19(12):3176-88. doi: 10.1158/1078-0432.CCR-13-0042. Epub 2013 Apr 24. — View Citation

* Note: There are 23 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete clinical resolution	This is the first of the three possible clinical outcome. The patient has achieved complete mucosal healing meaning there is no signs of bone exposure or fistula, the patient is asymptomatic and thus, can be considered cured.	Third month
Primary	Clinically stable disease	Second possible clinical outcome. The patient has not been cured but has neither gotten worse meaning that the area of bone exposure (in square centimeters) is equal or not greater than 50 percent of the initial measurement, and has not developed disease up-staging.	Third month
Primary	Clinical progression or up-staging	Third possible clinical outcome. The patient has gotten worse meaning that the area of bone exposure (in square centimeters) is greater than 50 percent of the initial measurement, or the patient has progressed to a higher stage.	Third month
Primary	Level of salivary NTX	Expressed in nanomoles of bone collagen equivalents	Third Month
Primary	Level of salivary MMP-9	Expressed in nanograms/milliliters	Third Month
Primary	Levels of IL-1a, IL-1b, IL-6, IL-17 and IL-36a.	Expressed in picograms/milliliters	Third Month
Secondary	Radiological absence of radiolucent areas or complete ossification.	This is the first of three possible radiological outcomes and means that the patient has no longer radiological signs of necrotic bone (sequestrum or osteolysis) in the CT or CB-CT scan.	Third month
Secondary	Radiologically stable disease	Second possible radiological outcome. The radiolucent lesion or sequestrum (measured in centimeters by the greater diameter in the CT or CB-CT scan) is equal or not greater than 50 percent of the initial measurement, and does not meet radiological up-staging criteria.	Third Month
Secondary	Radiological progression	Third possible radiological outcome. The radiolucent lesion or sequestrum (measured in centimeters by the greater diameter in the CT or CB-CT scan) is greater than 50 percent of the initial measurement, or meets radiological up-staging criteria.	Third month